Noninvasive mechanical ventilation in early acute respiratory distress syndrome

Helmet Continuous Positive Airway Pressure in COVID-19 Related Acute Respiratory Distress Syndrome in Respiratory Intermediate Care Unit

“…In addition, of the 56 patients in the "severe ARDS" group, 31 were transferred to ICU and, of these, 15 finally survived, with a mortality rate of 48%, in agreement with the mortality rate described for patients with severe ARDS in ICU (45%). We underline that, in our group of patients, mortality rates in mild and moderate ARDS are inferior to those reported in literature [5,17], considering the different features of patients admitted to ICUs (i.e. multiorgan failure).…”

“…The use of NIV in "de novo" ARDS has received a growing interest over the last decades in order to avoid complications related to IMV. Until the outbreak of COVID-19 pandemic, evidence suggested to limit this treatment to carefully selected patients with mild to moderate ARDS (failure in fact is higher than 50% in severe ARDS) and applied in experienced centers with close monitoring of blood gases and respiratory mechanics in order to avoid delayed intubation in case of failure [17,18].…”

A systematic review and meta-analysis of different mask ventilation schemes on management of general anesthesia in patients with respiratory failure

“…The method of NIV provides patients with respiratory support through a non-invasive interface, which can maintain patients' swallowing and expectoration ability and reduce the incidence of ventilators associated with pneumonia (23,24). However, non-invasive mechanical ventilation is often interrupted due to patient intolerance, leading to treatment failure (25). The cause of interruption may be related to the human-computer interaction of NIV.…”

Interferon-β-1a for patients with moderate to severe acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials

“…6 Currently, the treatment of ARDS is based principally on supportive care, management of the underlying disease, and ventilator support. 7 Preliminary evidence from a small, open -label, phase 1/2 study revealed some benefit of reducing 28 -day mortality in patients with ARDS treated with interferon beta -1a compared with those treatment -naive. 6 Acute respiratory distress syndrome is associated with severe morbidity and mortality.…”